Steve Tuplin/LinkedIn
Dec 6, 2025, 11:50
Steve Tuplin on Roche’s Mission at ASH25
Steve Tuplin, VP, Global Disease Area Head – Hematology and ai Oncology at Roche, shared on LinkedIn:
”Next stop: Orlando!
While many head there for the thrill rides, we are heading to ASH25 for a different kind of excitement: the breakthroughs shaping the future of haematology.
We are looking forward to sharing how our broad portfolio is evolving to meet the real-world needs of patients and the healthcare system.
It’s not about magic; it’s about our unwavering commitment to raising the therapeutic bar and delivering innovation that truly matters.
I’m excited to catch up with those of you attending.
Let me know—what is top of your list for this year?”
All from ASH25 featured in Hemostasis Today.
-
Dec 6, 2025, 18:02ASH25 Day 1: Don’t Miss The Highlights
-
Dec 6, 2025, 15:44Atul Gupta on Where The Healthcare Innovation is Headed
-
Dec 6, 2025, 15:22Nathan White on How Inflammation Contributes to Coagulopathy After Trauma
-
Dec 6, 2025, 15:02Anas Younes on AstraZeneca’s Aims in Blood Cancer to Be Presented at ASH25
-
Dec 6, 2025, 14:08David Alderman: ASH25 is Live
-
Dec 6, 2025, 13:53Isabelle Mahé Presents The Proposals from INNOVTE CAT Working Group
-
Dec 6, 2025, 11:13Khaled Musallam on The Lancet Haematology Podcast: Your ASH25 Roadmap
-
Dec 5, 2025, 03:46Sreeni Sivan Pillai: Preventing Thrombophlebitis and Upper Limb DVT in PICC Lines
-
Dec 5, 2025, 03:45Ardeshir Khademi: A Clinical Lesson on Thrombophilia, Silent Infarcts, and Asking the Right Questions